OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents.

Colm D Andrews,Edward P K Parker,Elsie Horne,Venexia Walker,Tom Palmer,Andrea L Schaffer,Amelia CA Green,Helen J Curtis,Alex J Walker,Lucy Bridges,Christopher Wood,Victoria Speed,Christopher Bates,Jonathan Cockburn,John Parry,Amir Mehrkar,Brian MacKenna,Sebastian CJ Bacon,Ben Goldacre,Miguel A Hernan,Jonathan AC Sterne,The OpenSAFELY Collaborative,William J Hulme
DOI: https://doi.org/10.1101/2024.05.20.24306810
2024-05-20
Abstract:Background Children and adolescents in England were offered BNT162b2 as part of the national COVID-19 vaccine roll out from September 2021. We assessed the safety and effectiveness of first and second dose BNT162b2 COVID-19 vaccination in children and adolescents in England. Methods With the approval of NHS England, we conducted an observational study in the OpenSAFELY-TPP database, including a) adolescents aged 12-15 years, and b) children aged 5-11 years and comparing individuals receiving i) first vaccination with unvaccinated controls and ii) second vaccination to single-vaccinated controls. We matched vaccinated individuals with controls on age, sex, region, and other important characteristics. Outcomes were positive SARS-CoV-2 test (adolescents only); COVID-19 A&E attendance; COVID-19 hospitalisation; COVID-19 critical care admission; COVID-19 death, with non-COVID-19 death and fractures as negative control outcomes and A&E attendance, unplanned hospitalisation, pericarditis, and myocarditis as safety outcomes. Results Amongst 820,926 previously unvaccinated adolescents, the incidence rate ratio (IRR) for positive SARS-CoV-2 test comparing vaccination with no vaccination was 0.74 (95% CI 0.72-0.75), although the 20-week risks were similar. The IRRs were 0.60 (0.37-0.97) for COVID-19 A&E attendance, 0.58 (0.38-0.89) for COVID-19 hospitalisation, 0.99 (0.93-1.06) for fractures, 0.89 (0.87-0.91) for A&E attendances and 0.88 (0.81-0.95) for unplanned hospitalisation. Amongst 441,858 adolescents who had received first vaccination IRRs comparing second dose with first dose only were 0.67 (0.65-0.69) for positive SARS-CoV-2 test, 1.00 (0.20-4.96) for COVID-19 A&E attendance, 0.60 (0.26-1.37) for COVID-19 hospitalisation, 0.94 (0.84-1.05) for fractures, 0.93 (0.89-0.98) for A&E attendance and 0.99 (0.86-1.13) for unplanned hospitalisation. Amongst 283,422 previously unvaccinated children and 132,462 children who had received a first vaccine dose, COVID-19-related outcomes were too rare to allow IRRs to be estimated precisely. A&E attendance and unplanned hospitalisation were slightly higher after first vaccination (IRRs versus no vaccination 1.05 (1.01-1.10) and 1.10 (0.95-1.26) respectively) but slightly lower after second vaccination (IRRs versus first dose 0.95 (0.86-1.05) and 0.78 (0.56-1.08) respectively). There were no COVID-19-related deaths in any group. Fewer than seven (exact number redacted) COVID-19-related critical care admissions occurred in the adolescent first dose vs unvaccinated cohort. Among both adolescents and children, myocarditis and pericarditis were documented only in the vaccinated groups, with rates of 27 and 10 cases/million after first and second doses respectively. Conclusion BNT162b2 vaccination in adolescents reduced COVID-19 A&E attendance and hospitalisation, although these outcomes were rare. Protection against positive SARS-CoV-2 tests was transient.
What problem does this paper attempt to address?
This paper aims to evaluate the safety and effectiveness of the BNT162b2 (Pfizer - BioNTech) COVID - 19 vaccine in children and adolescents in England. Specifically, the study focuses on the following aspects: 1. **Effectiveness of the vaccine**: - **Comparison between the first vaccination and non - vaccination**: Evaluate the changes in the risk of positive SARS - CoV - 2 tests, COVID - 19 emergency department visits, hospitalizations, intensive care unit (ICU) admissions, and deaths after the first dose of the BNT162b2 vaccine, compared with the unvaccinated control group. - **Comparison between the second vaccination and single - dose vaccination**: Evaluate the changes in the above - mentioned indicators after the second dose of the BNT162b2 vaccine, compared with the control group that has only received one dose. 2. **Safety of the vaccine**: - Evaluate adverse reactions after vaccination, especially the incidence of myocarditis and pericarditis. - Compare the differences in emergency department visits, unplanned hospitalizations, etc. between the vaccinated group and the unvaccinated or single - dose - vaccinated control group. ### Main research results - **Effectiveness of the first vaccination**: - The incidence rate ratio (IRR) of positive SARS - CoV - 2 tests was 0.74 (95% confidence interval [CI] 0.72 - 0.75), but the risks were similar within 20 weeks. - The IRR of COVID - 19 emergency department visits was 0.60 (0.37 - 0.97), and the IRR of hospitalizations was 0.58 (0.38 - 0.89). - The IRR of fractures (negative control outcome) was 0.99 (0.93 - 1.06), the IRR of emergency department visits was 0.89 (0.87 - 0.91), and the IRR of unplanned hospitalizations was 0.88 (0.81 - 0.95). - **Effectiveness of the second vaccination**: - The IRR of positive SARS - CoV - 2 tests was 0.67 (0.65 - 0.69). - The IRR of COVID - 19 emergency department visits was 1.00 (0.20 - 4.96), and the IRR of hospitalizations was 0.60 (0.26 - 1.37). - The IRR of fractures was 0.94 (0.84 - 1.05), the IRR of emergency department visits was 0.93 (0.89 - 0.98), and the IRR of unplanned hospitalizations was 0.99 (0.86 - 1.13). - **Safety**: - Myocarditis and pericarditis mainly occurred in the vaccinated group, with 27 and 10 cases per million vaccinated individuals after the first and second doses, respectively. - Severe COVID - 19 - related events (such as ICU admissions and deaths) were very rare in children and adolescents. ### Conclusion Vaccination with the BNT162b2 vaccine in adolescents can reduce the risks of COVID - 19 - related emergency department visits and hospitalizations, although these events are relatively rare themselves. The protective effect of the vaccine against positive SARS - CoV - 2 tests is temporary. In children, it is difficult to accurately estimate the effectiveness of the vaccine because severe events are very rare. Although myocarditis and pericarditis are rare, they mainly occur in the vaccinated group. Overall, the protective effect of the vaccine in adolescents is greater than its potential risks.